Powerfully Simple Glucose Monitoring
Better Accuracy* & Health Outcomes1-5
Why Dexcom G7?
Powerfully Simple Glucose Monitoring
Minimal Training, Maximum Benefits, making it a valuable addition to diabetes management for you and your patients. Dexcom G7 is now easier than ever to use and seamlessly integrates into your patient's lifestyle, promoting consistent monitoring without disrupting their daily routine.
| On Average it takes HCPs 7 Minutes to set up the Dexcom G7 with half the amount of steps as G66 |  | Easy to insert: Simple, painless, one-push applicator with all-in-one sensor7 |
| Adults 65+ report high usability with a set up time of 12 minutes6 |
| New and easy self-onboarding training modules in the app |
|
Customised alerts to suit people living with diabetes’ lifestyle and needs with the new
|
How does Dexcom G7 Work?
Dexcom G7 is approved for wear on the arm and abdomen, and ages 2-7 can wear Dexcom G7 on the upper buttocks
Superior Accuracy*
Dexcom G7 is our most accurate CGM system8 giving people living with diabetes the confidence to make informed diabetes decisions. Dexcom CGM systems have been studied in over 250 registered clinical trials.#
- 8.2% overall adult MARD‡ (back of the arm)9
- 95.3% of the sensor readings (upper arm) fall within ±1.1 mmol/L of the YSI blood glucose values <3.9 mmol/L and within ±20% of YSI blood glucose values ≥3.9 mmol/L9,10
- 8.1% overall paediatric MARD‡ (back of the arm)10
- For Paediatrics, after the initial 24 hours the MARD was below 8% for the remaining days of wear10
Improved Health Outcomes with more
Protection from Hypo and Hyperglycaemia^
Dexcom G7 offers predictive alerts with the Urgent Low Soon (ULS), enabling proactive intervention to prevent sever hypoglycaemia and reducing rebound hyperglycaemia11
Dexcom G7 CGM has been proven to:
- Reduce HbA1C by 1%1
- Reduce hypoglycaemia by 40%11
- Reduce rebound hyperglycaemic events12
- Increase time in range by 11.2% for MDI users and 14.5% for CSII users13
- Improve overall wellbeing and quality of life14
- Provide exceptional accuracy for better informed treatment decisions
References:
*As compared to Dexcom G6 System
# clinicaltrials.gov
^ As compared to SMBG
1. Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-8
2. Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3. Martens T, et al. JAMA. 2021;325(22):2262-2272.
4. Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
5. Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143 76.
6.Psavko S, et al. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
7. Dexcom G7 CGM System User Guide
8. Welsh JB, et al. Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems. J Diabetes Sci Technol. 2024;18(1):143-7.
9. Garg SK, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022;24(6):373-80.
10. Laffel LM,et al. Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes. J Diabetes Sci Technol. 2023;17(4):962-7.
11. Puhr S, et al. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019;21(4):155-8.
12. Acciaroli G, et al. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022;16(3):677-82;
13.Šoupal J, et al. Glycemic Outcomes in Adults with T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow‐Up from The COMISAIR Study. Diabetes Care. 2020;43:37-43.
14.Lind M, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-87.